Document:

Exhibit 10.1

 

 

SUBSCRIPTION AGREEMENT

 

This Subscription
Agreement (this “Agreement”) is made as of the date set forth on the signature page hereto, by and
among Bionik Laboratories Corp., a Delaware
corporation (the “Company”), and the subscribers identified on the signature pages hereto (each, a “Subscriber”
and collectively, the “Subscribers”).

 

Recitals

Whereas,
in June 2022, the Company commenced an offering to sell up to US$500,000 in Convertible Promissory Notes in the form annexed hereto as
Exhibit A (each, a “Note” and collectively, the “Notes”) pursuant to Section 4(a)(2)
of the Securities Act of 1933, as amended (the “Securities Act”), Rule 506(b) of Regulation D and/or Regulation
S as promulgated under the Securities Act (the “Offering”); and

 

Whereas,
the Subscribers wish to purchase Notes in the amount set forth on (the “Subscription Amount”) their respective
Signature Page to this Agreement or a counterpart to this Agreement.

 

Now,
Therefore, in consideration of the mutual
covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged,
the Company and the Subscribers hereby agree as follows:

 

1.         PURCHASE OF CONVERTIBLE PROMISSORY NOTES.

 

1.1      Subscription. Subject to the terms and conditions herein, each Subscriber will
loan to the Company such amount, and the Company shall borrow from each Subscriber, in accordance with the respective Subscription Amount
and at such date as mutually agreed upon between the Company and each Subscriber (each such date, a “Funding Date”).

 

1.2      Payment for Subscription. Each Subscriber agrees that the Subscription Amount
to the Company for the amount of the Subscriber’s subscription hereunder is to be made upon the applicable Closing (as defined below),
by check or by wire transfer to an account designated by the Company.

 

1.3      Closing.

 

(a)       The closing of the subscriptions for the Notes shall occur on each Funding Date (collectively, the “Closings”
and each, without distinction, a “Closing”). Each Closing shall be held remotely by the electronic exchange
of documents and funds at such time and by such means upon which the Company and the Subscribers purchasing the Notes at such Closing
shall agree.

 

(b)       At each Closing, the Company shall deliver to the Subscribers executed Notes in the amounts determined for each Purchaser pursuant
to this Section 1.

 

    	 	1	 

     

    

 

2.      REPRESENTATIONS AND WARRANTIES.

 

2.1      Representations and Warranties by the Company. The Company represents and warrants
to each Subscriber that:

 

(a)      Authorization. The Company has all corporate right, power and authority to enter into this Agreement and to consummate the
transactions contemplated hereby. All corporate action on the part of the Company, its directors and stockholders necessary for the: (i)
authorization execution, delivery and performance of this Agreement by the Company; (ii) authorization, sale, issuance and delivery of
the Notes contemplated hereby and the performance of the Company’s obligations hereunder; and (iii) authorization, issuance and
delivery of the securities issuable upon conversion of the Notes has been taken. The securities issuable upon conversion of the Notes
will be validly issued, fully paid and nonassessable.

 

(b)      Enforceability. Assuming this Agreement has been duly and validly authorized, executed and delivered by the parties hereto
and thereto other than the Company, this Agreement is duly authorized, executed and delivered by the Company constitutes the legal, valid
and binding obligations of the Company enforceable against the Company in accordance with its terms, except as such enforcement is limited
by general equitable principles, or by bankruptcy, insolvency and other similar laws affecting the enforcement of creditors rights generally.

 

(c)      No Violations. The execution, delivery and performance of this Agreement and the Notes by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby will not (i) result in a violation of the Certificate of Incorporation
of the Company or other organizational documents of the Company, (ii) conflict with, or constitute a default (or an event which with notice
or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation
of, any agreement, indenture or instrument to which the Company is a party, or (iii) result in a violation of any law, rule, regulation,
order, judgment or decree applicable to the Company by which any property or asset of the Company is bound or affected.

 

2.2     Disclaimer. It is specifically understood and agreed by each Subscriber that
the Company has not made, nor by this Agreement shall be construed to make, directly or indirectly, explicitly or by implication, any
representation, warranty, projection, assumption, promise, covenant, opinion, recommendation or other statement of any kind or nature
with respect to the anticipated profits or losses of the Company, except as otherwise provided with this Agreement.

 

2.3     Representations and Warranties by the Subscribers. Each Subscriber represents
and warrants to the Company that:

 

(a)     The Subscriber is acquiring the Notes for the Subscriber’s own account, as principal, for investment purposes only and
not with any intention to resell, distributes or otherwise dispose of the Notes, in whole or in part.

 

(b)    The Subscriber has had an unrestricted opportunity to: (i) obtain information concerning the Offering, including the Notes,
the Company and its proposed and existing business and assets; (ii) ask questions of, and receive answers from the Company concerning
the terms and conditions of the Offering; and (iii) to obtain such additional information as may have been necessary to verify the accuracy
of the information contained in this Agreement or otherwise provided.

 

    	 	2	 

     

    

 

(c)    The Subscriber has such knowledge and experience in financial and business matters that he is capable of evaluating the merits
and risks of investing in the Company, and all information that the Subscriber has provided concerning the Subscriber, the Subscriber’s
financial position and knowledge of financial and business matters is true, correct and complete.

 

(d)    The Subscriber has relied solely on the advice of, or has consulted with, in regard to the legal, investment and tax considerations
involved in the purchase, ownership and disposition of Notes, the Subscriber’s own legal counsel, business and/or investment adviser,
accountant and tax adviser.

 

(e)    If the Subscriber is an entity, the Subscriber is duly organized, validly existing and in good standing under the laws of its
jurisdiction of incorporation or organization, as the case may be. The Subscriber has all requisite power and authority to own its properties,
to carry on its business as presently conducted, to enter into and perform this Agreement, the Notes and the agreements, documents and
instruments executed, delivered and/or contemplated hereby (collectively, the “Subscription Documents”) to which
it is a party and to carry out the transactions contemplated hereby and thereby. The Subscription Documents are valid and binding obligations
of the Subscriber, enforceable against it in accordance with their terms, except as enforceability may be limited by applicable bankruptcy,
insolvency, moratorium, reorganization or similar laws, from time to time in effect, which affect enforcement of creditors’ rights
generally. If applicable, the execution, delivery and performance of the Subscription Documents to which it is a party have been duly
authorized by all necessary action of the Subscriber. The execution, delivery and performance of the Subscription Documents and the performance
of any transactions contemplated by the Subscription Documents will not: (i) violate, conflict with or result in a default (whether after
the giving of notice, lapse of time or both) under any contract or obligation to which the Subscriber is a party or by which it or its
assets are bound, or any provision of its organizational documents (if an entity), or cause the creation of any lien or encumbrance upon
any of the assets of the Subscriber; (ii) violate, conflict with or result in a default (whether after the giving of notice, lapse of
time or both) under, any provision of any law, regulation or rule, or any order of, or any restriction imposed by any court or other governmental
agency applicable to the Subscriber; (iii) require from the Subscriber any notice to, declaration or filing with, or consent or approval
of any governmental authority or other third party other than pursuant to federal or state securities or blue sky laws; or (iv) accelerate
any obligation under, or give rise to a right of termination of, any agreement, permit, license or authorization to which the Subscriber
is a party or by which it is bound.

 

(f)     At the time the Subscriber was offered the Notes, it was, and at the date hereof it is, and on each Funding Date and date on
which the Subscriber converts the Notes the Subscriber will be, an “accredited investor” as defined in Rule 501(a) under the
Securities Act. The Subscriber hereby represents that neither the Subscriber nor any of its Rule 506(d) Related Parties is a “bad
actor” within the meaning of Rule 506(d) promulgated under the Securities Act. For purposes of this Agreement, “Rule
506(d) Related Party” shall mean a person or entity covered by the “Bad Actor disqualification” provision of
Rule 506(d) of the Securities Act.

 

    	 	3	 

     

    

 

3.       MISCELLANEOUS.

 

3.1     Addresses and Notices. All notices, demands, consents, requests, instructions
and other communications to be given or delivered or permitted under or by reason of the provisions of this Agreement or in connection
with the transactions contemplated hereby shall be in writing and shall be deemed to be delivered and received by the intended recipient
as follows: (i) if personally delivered, on the business day of such delivery (as evidenced by the receipt of the personal delivery service);
(ii) if mailed certified or registered mail return receipt requested, two (2) business days after being mailed; or (iii) if delivered
by overnight courier (with all charges having been prepaid), on the business day of such delivery (as evidenced by the receipt of the
overnight courier service of recognized standing). If any notice, demand, consent, request, instruction or other communication cannot
be delivered because of a changed address of which no notice was given (in accordance with this Section 3.1, or the refusal to
accept same, the notice, demand, consent, request, instruction or other communication shall be deemed received on the second business
day the notice is sent (as evidenced by a sworn affidavit of the sender). All such notices, demands, consents, requests, instructions
and other communications will be sent to the following addresses or facsimile numbers as applicable:

 

	If to the Company to:	 	
    Bionik Laboratories Corp.

    80 Coolidge Hill Road

    Watertown, MA 02472

    Attention: CEO

	 	 	 
	With copies to:	 	
    Ruskin Moscou Faltischek, PC

    1425 RXR Plaza

    East Tower, 15th Floor

    Uniondale, New York 11556

    Attention: Stephen E. Fox, Esq.

 

If to the Subscriber, to the address set forth
on the signature page annexed hereto.

 

Any such person may by notice given in accordance
with this Section 3.1 to the other parties hereto designate another address or person for receipt by such person of notices hereunder.

 

3.2     itles
and Captions. All Article and Section titles or captions in this Agreement are for convenience only. They shall not
be deemed part of this Agreement and do not in any way define, limit, extend or describe the scope or intent of any provisions hereof.

 

3.3     Assignability. This Agreement is not transferable or assignable by the Company
without the prior written consent of the undersigned. This Agreement is not transferable or assignable by the undersigned without the
prior written consent of the Company; provided, however, that the consent of the Company shall not be required in connection with a proposed
assignment to any fund or account managed by the same investment manager as the Subscriber or an affiliate of the Subscriber, subject
to such transferee or assignee, as applicable, executing a joinder to this Agreement or a separate subscription agreement in the same
form as this Agreement.

 

    	 	4	 

     

    

 

3.4      Pronouns and Plurals. Whenever the context may require, any pronoun used herein
shall include the corresponding masculine, feminine or neuter forms. The singular form of nouns, pronouns and verbs shall include the
plural and vice versa.

 

3.5      Further Action. The parties shall execute and deliver all documents, provide
all information and take or forbear from taking all such action as may be necessary or appropriate to achieve the purposes of this Agreement.
Each party shall bear its own expenses in connection therewith.

 

3.6      Applicable Law. This Agreement shall be construed in accordance with and governed
by the laws of the State of Delaware without regard to its conflict of law rules.

 

3.7       Binding Effect. This Agreement shall be binding upon and inure to the benefit
of the parties hereto and their respective heirs, administrators, successors, legal representatives, personal representatives, permitted
transferees and permitted assigns. If the undersigned is more than one person, the obligation of the undersigned shall be joint and several
and the agreements, representations, warranties and acknowledgments herein contained shall be deemed to be made by and be binding upon
each such person and such person’s heirs, executors, administrators and successors.

 

3.8        Integration. This Agreement, together with the remainder of the Subscription
Documents of which this Agreement forms a part, constitutes the entire agreement among the parties pertaining to the subject matter hereof
and supersedes and replaces all prior and contemporaneous agreements and understandings, whether written or oral, pertaining thereto.
No covenant, representation or condition not expressed in this Agreement shall affect or be deemed to interpret, change or restrict the
express provisions hereof.

 

3.9        Amendment.  This Agreement and the Notes may be amended only with the written
consent of the Company and the holders of a majority of the aggregate principal amount of the Notes (a “Majority in Interest”).
The conditions or observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively
or prospectively) only by written instrument and with respect to conditions or performance obligations benefiting the Company, by the
Company, and with respect to conditions or performance obligations benefiting the Subscribers, only with the consent of a Majority in
Interest. Any amendment or waiver effected in accordance with this Section 3.9 shall be binding on all holders of the Notes, even
if they do not execute such amendment, consent or waiver, as the case may be.

 

3.10      Creditors.  None of the provisions of this Agreement shall be for the benefit
of or enforceable by creditors of any party.

 

3.11     Waiver.  No failure by any party to insist upon the strict performance of any
covenant, agreement, term or condition of this Agreement or to exercise any right or remedy available upon a breach thereof shall constitute
a waiver of any such breach or of such or any other covenant, agreement, term or condition.

 

    	 	5	 

     

    

 

3.12      Rights and Remedies. The rights and remedies of each of the parties hereunder
shall be mutually exclusive, and the implementation of one or more of the provisions of this Agreement shall not preclude the implementation
of any other provision.

 

3.13      Counterparts. This Agreement may be executed in one or more counterparts, each
of which will be deemed to be an original copy of this Agreement and all of which, when taken together, will be deemed to constitute one
and the same agreement. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf”
format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.

 

signatures
on the following pages

 

 

 

 

 

    	 	6	 

     

    

 

In
Witness Whereof, the undersigned has executed this Agreement on this ____ day of June, 2022.

  

	Signature of Subscriber: 	 	 
	 	 	 	 
	By:	 	 	 
	Name: 	 	 	Print Name of Subscriber
	Title: 	 	 	 
	 	 	 	 
	 	 	 
	Social Security Number(s) or EIN 	 	 
	 	 	 	 
	 	 	 	 
	Mailing Address of Subscriber(s) 	 	Residence of Subscriber(s)
	 	 	 
	Street 	 	Street
	 	 	 
	 	 	 
	City        State       Zip Code 	 	City       State       Zip Code

  

If Joint Ownership, check one:

 

		 ̈	Joint Tenants with Right of Survivorship

		 ̈	Tenants-in-Common

		 ̈	Tenants by the Entirety

		 ̈	Community Property

		 ̈	Other (specify):__________________________

 

	 	$	 
	 	 	Aggregate Subscription Amount 
	 	 	 
	 	 	 
	 	 	Method of Payment:   ̈ Wire Transfer  
	 	 	 ̈ Check

 

FOREGOING SUBSCRIPTION ACCEPTED:

 

Bionik
Laboratories Corp.

 

	By:	 	 

Name:

Title:

 

    Signature Page to Subscription Agreement

     

    

 

 

 

Exhibit
A 

 

CONVERTIBLE PROMISSORY NOTE

 

[See attached]Exhibit 10.2

 

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE
UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD,
ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS
OF SUCH ACT OR SUCH LAWS. 

 

_______________________________

 

BIONIK LABORATORIES CORP.

 

SECURED CONVERTIBLE PROMISSORY NOTE

 

	Principal Amount: US$[___]	Issue Date: June [__], 2022

 

Bionik
Laboratories Corp., a Delaware corporation (the “Company”), for value received, hereby promises to
pay to [_____] or its permitted assigns or successors (the “Holder”), the principal amount of [_____] Dollars
(US$[___]) (the “Principal Amount”), without demand, on the Maturity Date (as hereinafter defined), together
with any accrued and unpaid interest due thereon. This Note shall bear interest at a fixed rate of 1% per month, beginning on the Issue
Date. Interest shall be computed based on a 360-day year of twelve 30-day months and shall be payable, along with the Principal Amount,
on the Maturity Date. Except as set forth in Section 3.1, payment of all principal and interest due shall be in such coin or currency
of the United States of America as shall be legal tender for the payment of public and private debts at the time of payment.

 

This Note is a convertible
promissory note referred to in that certain Subscription Agreement dated as of the date hereof, or series of like subscription agreements
(individually or collectively, the “Subscription Agreement”), among the Company and the subscribers named therein,
pursuant to which the Company is seeking to borrow up to $500,000 (the “Offering”).

 

1.       Definitions.

 

1.1    Definitions. The terms defined in this Section 1 whenever used in this
Note shall have the respective meanings hereinafter specified.

 

“Common Stock”
means the common stock, par value $0.001 per share, of the Company.

 

“Conversion Date”
shall mean the date, if any, of the conversion of this Note into Conversion Shares, as provided in Section 3.1.

 

“Conversion Shares”
means the New Round Stock or Common Stock, as applicable, issued or issuable to the Holder pursuant to Article 3.

 

“Event of Default”
shall have the meaning set forth in Section 5.1.

 

“Holder”
or “Holders” means the person named above or any Person who shall thereafter become a recordholder of this Note
in accordance with the terms hereof.

 

    	 	1	 

     

    

 

“Issue Date”
means the issue date stated above.

 

“Maturity Date”
shall mean the two (2) year anniversary of the Issue Date.

 

“Note”
means this Convertible Note, as amended, modified or restated.

 

“New Round Stock”
means, the securities (or units of securities if more than one security are sold as a unit) issued by the Company in one or more tranches
in the context of the Qualified Financing.

 

“Person”
means an individual, corporation, partnership, limited liability company, association, trust, joint venture, unincorporated organization
or any government, governmental department or agency or political subdivision thereof.

 

“Qualified Financing”
means the next equity or equity linked round of financing of the Company for cash proceeds.

 

“Securities Act”
means the United States Securities Act of 1933, as amended.

 

2.      GENERAL PROVISIONS.

 

2.1    Loss, Theft, Destruction of Note. Upon receipt of evidence satisfactory to the
Company of the loss, theft, destruction or mutilation of this Note and, in the case of any such loss, theft or destruction, upon receipt
of indemnity or security reasonably satisfactory to the Company, or, in the case of any such mutilation, upon surrender and cancellation
of this Note, the Company will make and deliver, in lieu of such lost, stolen, destroyed or mutilated Note, a new Note of like tenor and
unpaid principal amount dated as of the date hereof. This Note shall be held and owned upon the express condition that the provisions
of this Section 2.1 are exclusive with respect to the replacement of a mutilated, destroyed, lost or stolen Note and shall preclude
any and all other rights and remedies notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to
the replacement of negotiable instruments or other securities without their surrender.

 

2.2     Prepayment; Redemption. This Note may not be prepaid by the Company in whole
or in part, except with the prior written consent of the Holder. This Note may not be redeemed by the Company in whole or in part, except
with the prior written consent of the Holder.

 

3.      CONVERSION OF NOTE.

 

3.1      Conversion.

 

(a)    Conversion upon Maturity Date. On the Maturity Date without any action on the part of the Holder, the outstanding principal
and accrued and unpaid interest under the Notes will be converted into shares of Common Stock at a conversion price equal to the closing
price of the Common Stock on the Maturity Date.

 

(b)    Conversion upon a Qualified Financing. Upon the consummation of a Qualified Financing, without any action on the part of the
Holder, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of New Round Stock based
upon the issuance (or conversion) price of New Round Stock.

 

    	 	2	 

     

    

 

(c)   
Upon and as of the Maturity Date or Conversion Date, as applicable, this Note will be cancelled on the books and records of
the Company and shall solely represent the right to receive the Conversion Shares.

 

3.2      Delivery of Securities Upon Conversion.

 

(a)     As soon as is practicable after the Maturity Date or Conversion Date, as applicable, the Company shall deliver to the Holder
a certificate or certificates evidencing the Conversion Shares issuable to the Holder.

 

(b)     The issuance of certificates for Conversion Shares upon conversion of this Note shall be made without charge to the Holder
for any issuance tax in respect thereof or other cost incurred by the Company in connection with such conversion and the related issuance
of securities. Upon conversion of this Note, the Company shall take all such actions as are necessary in order to ensure that the Conversion
Shares so issued upon such conversion shall be validly issued, fully paid and nonassessable.

 

3.3    Fractional Shares. No fractional shares or scrip representing fractional shares
shall be issued upon conversion of this Note. If any conversion of this Note would create a fractional share or a right to acquire a fractional
share, the Company shall round to the nearest whole number.

 

4.           STATUS; RESTRICTIONS ON TRANSFER.

 

4.1     Status of Note. This Note is a direct, general and unconditional obligation of
the Company, and constitutes a valid and legally binding obligation of the Company, enforceable in accordance with its terms subject,
as to enforcement, to bankruptcy, insolvency, reorganization and other similar laws of general applicability relating to or affecting
creditors’ rights and to general principles of equity. This Note does not confer upon the Holder any right to vote or to consent
or to receive notice as a stockholder of the Company, as such, in respect of any matters whatsoever, or any other rights or liabilities
as a stockholder, prior to conversion hereof into Conversion Shares.

 

4.2     Restrictions on Transferability. This Note and any Conversion Shares issued with
respect to this Note, have not been registered under the Securities Act, or under any state securities or so-called “blue sky laws,”
and may not be offered, sold, transferred, hypothecated or otherwise assigned except (a) pursuant to a registration statement with respect
to such securities which is effective under the Act or (b) upon receipt from counsel satisfactory to the Company of an opinion, which
opinion is satisfactory in form and substance to the Company, to the effect that such securities may be offered, sold, transferred, hypothecated
or otherwise assigned (i) pursuant to an available exemption from registration under the Act and (ii) in accordance with all applicable
state securities and so-called “blue sky laws.” The Holder agrees to be bound by such restrictions on transfer. The Holder
further consents that the certificates representing the Conversion Shares that may be issued with respect to this Note may bear a restrictive
legend to such effect.

 

    	 	3	 

     

    

 

5.          REMEDIES.

 

5.1       Events of Default. “Event of Default” wherever used herein
means any one of the following events:

 

(a)     The Company shall fail to issue and deliver the Conversion Shares in accordance with Section 3;

 

(b)     Default in the due and punctual payment of the principal of, or any other amount owing in respect of (including interest),
this Note when and as the same shall become due and payable;

 

(c)     Default in the performance or observance of any covenant or agreement of the Company in this Note (other than a covenant or
agreement a default in the performance of which is specifically provided for elsewhere in this Section 5.1), and the continuance
of such default for a period of 10 days after there has been given to the Company by the Holder a written notice specifying such default
and requiring it to be remedied;

 

(d)     The entry of a decree or order by a court having jurisdiction adjudging the Company as bankrupt or insolvent; or approving
as properly filed a petition seeking reorganization, arrangement, adjustment or composition of or in respect of the Company under the
Federal Bankruptcy Code or any other applicable federal or state law, or appointing a receiver, liquidator, assignee, trustee or sequestrator
(or other similar official) of the Company or of any substantial part of its property, or ordering the winding-up or liquidation of its
affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 calendar days;

 

(e)     The institution by the Company of proceedings to be adjudicated as bankrupt or insolvent, or the consent by it to the institution
of bankruptcy or insolvency proceedings against it, or the filing by it of a petition or answer or consent seeking reorganization or relief
under the Federal Bankruptcy Code or any other applicable federal or state law, or the consent by it to the filing of any such petition
or to the appointment of a receiver, liquidator, assignee, trustee or sequestrator (or other similar official) of the Company or of any
substantial part of its property, or the making by it of an assignment for the benefit of creditors;

 

(f)      The Company seeks the appointment of a statutory manager or proposes in writing or makes a general assignment or an arrangement
or composition with or for the benefit of its creditors or any group or class thereof or files a petition for suspension of payments or
other relief of debtors or a moratorium or statutory management is agreed or declared in respect of or affecting all or any material part
of the indebtedness of the Company; or

 

(g)     It becomes unlawful for the Company to perform or comply with its obligations under this Note.

 

5.2     Effects of Default. If an Event of Default occurs and is continuing, then and
in every such case the Holder may declare this Note to be due and payable immediately, by a notice in writing to the Company, and upon
any such declaration, the Company shall pay to the Holder the outstanding principal amount of this Note plus all accrued and unpaid interest
through the date the Note is paid in full. Holder shall further have the right to exercise any and all rights and remedies provided for
herein, under the Uniform Commercial Code and at law or equity generally.

 

    	 	4	 

     

    

 

5.3     Remedies Not Waived; Exercise of Remedies. No course of dealing between the Company
and the Holder or any delay in exercising any rights hereunder shall operate as a waiver by the Holder. No failure or delay by the Holder
in exercising any right, power or privilege under this Note shall operate as a waiver thereof nor shall any single or partial exercise
thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. By acceptance hereof, the
Holder acknowledges and agrees that this Note is one of a series of Convertible Promissory Notes of similar tenor issued by the Company
pursuant to the Offering (collectively, the “Related Notes”) and that upon the occurrence and during the continuance
of any Event of Default, the holders of a majority in original principal amount of the Related Notes, including this Note, shall have
the right to act on behalf of the holders of all such Notes in exercising and enforcing all rights and remedies available to all of such
holders under this Note, including, without limitation, foreclosure of any judgment lien on any assets of the Company. By acceptance hereof,
the Holder agrees not to independently exercise any such right or remedy without the consent of the holders of a majority in original
principal amount of the Related Notes (for the avoidance of doubt, including this Note).

 

6.        MISCELLANEOUS.

 

6.1      Severability. If any provision of this Note shall be held to be invalid or unenforceable,
in whole or in part, neither the validity nor the enforceability of the remainder hereof shall in any way be affected.

 

6.2      Notice. Where this Note provides for notice of any event, such notice shall be
given (unless otherwise herein expressly provided) in writing and either (a) delivered personally, (b) sent by certified, registered or
express mail, postage prepaid or (c) sent by facsimile or other electronic transmission, and shall be deemed given when so delivered personally,
sent by facsimile or other electronic transmission (confirmed in writing) or mailed. Notices shall be addressed, if to Holder, to its
address as provided in the Subscription Agreement or, if to the Company, to its principal office.

 

6.3      Governing Law. This Note shall be governed by, and construed in accordance with,
the laws of the State of Delaware (without giving effect to any conflicts or choice of law provisions that would cause the application
of the domestic substantive laws of any other jurisdiction).

 

6.4       Forum. The Holder and the Company hereby agree that any dispute which may arise
out of or in connection with this Note shall be adjudicated before a court of competent jurisdiction in the State of Delaware and they
hereby submit to the exclusive jurisdiction of the courts of the State of Delaware, as well as to the jurisdiction of all courts to which
an appeal may be taken from such courts, with respect to any action or legal proceeding commenced by either of them and hereby irrevocably
waive any objection they now or hereafter may have respecting the venue of any such action or proceeding brought in such a court or respecting
the fact that such court is an inconvenient forum.

 

    	 	5	 

     

    

 

6.5      Headings. The headings of the Articles and Sections of this Note are inserted
for convenience only and do not constitute a part of this Note.

 

6.6      Amendments. This Note may be amended or waived only with the written consent
of the Company and the holders of a majority in original aggregate principal amount of this Note and the other Related Notes. Any such
amendment or waiver shall be binding on all holders of the Notes, even if they do not execute such consent, amendment or waiver.

 

6.7      No Recourse Against Others. The obligations of the Company under this Note are
solely obligations of the Company and no officer, employee or stockholder shall be liable for any failure by the Company to pay amounts
on this Note when due or perform any other obligation.

 

6.8      Assignment; Binding Effect. This Note may not be assigned by the Company without
the prior written consent of the Holder. This Note shall be binding upon and inure to the benefit of both parties hereto and their respective
permitted successors and assigns.

 

Signature
on the Following Page

 

 

 

    	 	6	 

     

    

 

In
Witness Whereof, the Company has caused this Note to be signed by its duly authorized officer on the date hereinabove written.

 

	 	Bionik Laboratories Corp.
	 	 
	 	 
	 	By:	 
	 	Name:
	 	Title:

 

 

 

 

    Signature Page to Convertible Promissory Note

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]